Ex vivo expansion of the highly cytotoxic human natural killer cell line NK-92 under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy

Cytotherapy

Volumn 5, Issue 3, 2003, Pages 259-272

  Tam, Y K ^a   Martinson, J A ^a   Doligosa, K ^a   Klingemann, Hans G ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CELL AGGREGATION; CELL CULTURE; CELL GROWTH; CELL LINE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CULTURE MEDIUM; EX VIVO STUDY; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; METHODOLOGY; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHODGKIN LYMPHOMA; SERUM; TYPES OF STUDY;

EID: 0042194439     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240310001523     Document Type: Article

References (45)

1. Barrett AJ, Malkovsky V. Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 1996;93:754-61.
2. Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol 2000;111:6-17.
3. Helg C, Starobinski M, Jeannet M et al. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymph 1998;29:301-13.
4. Dazzi F, Goldman J. Donor lymphocyte infusions. Curr Opin Hematol 1999;6:394-9.
5. Feinstein L, Storb R. Nonmyeloablative hematopoietic cell transplantation. Curr Opin Oncol 2001;13:95-100.
6. Vindelov L. Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT). Eur J Haematol 2001;66:73-82.
7. Herr W, Schneider J, Lhose AW et al. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1996;191:131-42.
8. Marincola FM, Rivoltini L, Salgaller ML et al. Differential anti-MART/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence of in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol 1996;19:266-77.
9. Maccalli C, Farina C, Sensi M et al. TCR beta-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*201+ melanoma patients. J Immunol 1997;158:5902-13.
10. Esche C, Shurin MR, Lotze MT. The use of dendritic cells for cancer vaccination. Curr Opin Mol Ther 1999;1:72-81.
11. Dhodapkar MV, Bhardwaj N. Active immunization of humans with dendritic cells. J Clin Immunol 2000;20:167-74.
12. Zitvogel L, Angevin E, Tursz T. Dendritic cell-based immunotherapy of cancer. Ann Oncol 2000;11(Suppl 3):199-205.
13. Reid DC. Dendritic cells and immunotherapy for malignant disease. Br J Haematol 2000;112:874-87.
14. Melder RJ, Rosenfeld CS, Herberman RB et al. Large-scale preparation of adherent lymphokine-activated killer (A-LAK) cells for adoptive immunotherapy in man. Cancer Immunol Immunother 1989;29:67-73.
15. Miller JS, Klingsporn S, Lund J et al. Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant 1994;14:555-62.
16. Pierson BA, McGlave PB, Hu WS et al. Natural killer cell proliferation is dependent on human serum and markedly increased utilizing an enriched supplemented basal medium. J Hematother 1995;4:149-58.
17. Pierson BA, Europa AF, Hu WS et al. Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreacter. J Hematother 1996;5:475-83.
18. Belldegrun A, Tso CL, Kaboo R et al. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy. J Immunother Emphasis Tumor Immunol 1996;19:149-61.
19. Ridolfi R, Flamini E, Riccobon A et al. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients. Cancer Immunol Immunother 1998;46:185-93.
20. Freedman RS, Kudelka AP, Kavanagh JJ et al. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin-2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 2000;6:2268-78.
21. Cesano A, Pierson G, Visonneau S et al. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets. Blood 1996;87:393-403.
22. Klingemann HG, Miyagawa B. Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells. Blood 1996;87:4913-4.
23. Klingemann HG, Wong E, Maki G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant 1996;2:68-75.
24. Lu P, Negrin R. Cellular immunotherapy following autologous hematopoietic progenitor cell transplantation. Biol Blood Bone Marrow Transplant 1997;3:113-21.
25. Gong JH, Maki G, Klingemann HG. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994;8:652-8.
26. Yan Y, Steinherz P, Klingemann HG et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 1998;4:2859-68.
27. Tam YK, Miyagawa B, Ho VC et al. Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. J Hematother 1999;8:281-90.
28. Tam YK, Maki G, Miyagawa B et al. Characterization of genetically altered, interleukin-2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther 1999;10:1359-73.
29. Maki G, Klingemann H-G, Martinson JA, Tam YK. Factors regulating the cytotoxic activity of the human natural killer cell line NK-92. J Hematoth Stem Cell Res 2000;10:369-83.
30. Klingemann HG, Phillips GL. Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia? Leuk Lymph 1995;16:397-405.
31. Nagler A, Ackerstein A, Or R et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-γ in lymphoma patients post autologous marrow or stem cell transplant. Blood 1997;89:3951-9.
32. Sobol RE, Fakhrai H, Shawler D et al. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 1995;2:164-7.
33. Simons JW, Mikhak B, Chang JF et al. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59:5160-8.
34. Panelli MC, Wunderlich J, Jeffries J et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma associated antigens MART-1 and gp100. J Immunother 2000;23:487-98.
35. Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894-903.
36. Lau R, Wang F, Jeffry G et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001;24:66-78.
37. Sussman JJ, Shu S, Sondak VK et al. Activation of T lymphocytes for the adoptive immunotherapy of cancer. Ann Surg Oncol 1994;1:296-306.
38. Semino C, Martini L, Queirolo P et al. Adoptive immunotherapy of advanced solid tumors: An eight-year clinical experience. Anticancer Res 1999;19:5645-9.
39. Hoffman DM, Girlitz BJ, Belldegrun A et al. Adoptive cellular therapy. Semin Oncol 2000;27:221-33.
40. Cesano A, Visonneau S, Cioe L et al. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J Clin Invest 1994;94:1076-84.
41. Cesano A, Visonneau S, Jeglum KA. A Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res 1996;56:3021-9.
42. Cesano A, Visonneau S, Pasquini S. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia. Cancer Res 1996;56:4444-52.
43. Visonneau S, Cesano A, Porter DL et al. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clin Cancer Res 2000;6:1744-54.
44. Tonn T, Becker S, Esser R et al. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematoth Stem Cell Res 2001;10:535-44.
45. Uherek C, Tonn T, Herrmann B et al. Retargeting of NK-cell cytolytic activity to ErbB2 expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002;100:1265-73.